It is yet to be determined whether MCL-1 antagonism is effective in clinical trials of BLBCs, but there are currently two Phase I clinical trials of MCL-1 BH3 mimetics in patients with multiple myeloma, a disease with a MCL-1 dependent etiology [200]. Here, MCL1 is linked to plasma cell myeloma.